1. Kaplan–Meier curve for progression-free survival for gefitinib versus doublet chemotherapy in three phase III trials in first-line nonsmall cell lung cancer harbouring an activating epidermal growth factor receptor (EGFR) mutation: a) patients with EGFR mut...
Kaplan–Meier curve for progression-free survival for gefitinib versus doublet chemotherapy in three phase III trials in first-line nonsmall cell lung cancer harbouring an activating epidermal growth factor receptor (EGFR) mutation: a) patients with EGFR mutation-positive status in the IRESSA Pan-Asia Study (IPASS; first-line setting) (: gefitinib; : carboplatin plus paclitaxel) (reproduced from [39] with permission from the publisher; © 2009 Massachusetts Medical Society. All rights reserved), b) the overall population (all EGFR mutation-positive) in the WJTOG3405 study (first-line setting) (: gefitinib; : cisplatin plus docetaxel) (reproduced from [44] with permission from the publisher; © 2010, with permission from Elsevier) and c) the overall population (all EGFR mutation-positive) in the NEJ002 study (first-line setting) (: gefitinib (n = 114); : carboplatin plus paclitaxel (n = 110)) (reproduced from [45] with permission from the publisher; © 2009 Massachusetts Medical Society. All rights reserved). PFS: progression-free survival; HR: hazard ratio. #: HR <1.00 favours gefitinib.
A.A. Armour, and C.L. Watkins Eur Respir Rev 2010;19:
©2010 by European Respiratory Society